CRISPR-Cas13a SHERLOCK assay for rapid and sensitive detection of chikungunya virus
Microbiology Spectrum · 2026
DOI: 10.1128/spectrum.02298-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Spectrum, 2026. Verfasst von Niracha Athipanyasilp und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Chikungunya virus, Chikungunya Fever, CRISPR-Cas Systems, Molecular Diagnostic Techniques. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Faculty of Medicine Siriraj Hospital, Mahidol University.
Abstract (Originalsprache)
Chikungunya virus (CHIKV), a major cause of acute febrile illness and joint pain, remains a significant public health threat in tropical regions. Rapid and accurate detection is essential for timely clinical management and outbreak control, particularly in resource-limited settings where real-time PCR (RT-qPCR) is often impractical. We developed and validated a SHERLOCK assay coupled with recombinase polymerase amplification for CHIKV RNA detection. Analytical performance was assessed by determining the limit of detection (LOD), cross-reactivity, clinical sensitivity and specificity, and predictive values. The assay achieved an LOD of 215 copies/reaction with no cross-reactivity against other alphaviruses or flaviviruses. Clinical testing of 146 plasma samples showed a sensitivity and specificity of 94.52% and 100% with lateral-flow readout and 97.26% and 100% with fluorescence readout, respectively. This study establishes a promising CRISPR-Cas13a-based SHERLOCK platform for CHIKV detection, demonstrating high analytical performance, rapid turnaround time, and potential for future adaptation to resource-limited settings. IMPORTANCE Early and accurate detection of chikungunya virus (CHIKV) is critical for outbreak control, especially in resource-limited settings, where real-time PCR is not feasible. This study demonstrates that the CRISPR-Cas13a-based SHERLOCK platform, combined with RPA, achieves high diagnostic accuracy and a low detection limit, comparable to RT-qPCR. The assay’s rapid turnaround time and simple lateral-flow readout make it a promising tool for point-of-care diagnostics during CHIKV outbreaks, potentially improving disease surveillance and clinical decision-making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
- Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
- School of Biomolecular Science & Engineering, Vidyasirimedhi Institute of Science and Technology, Rayong, Thailand.
ORCID-Profile: Nasikarn Angkasekwinai, Navin Horthongkham
Förderung
- Faculty of Medicine Siriraj Hospital, Mahidol University
Zitieren
APA
Athipanyasilp, N., Saowpak, S., Chaimayo, C., Angkasekwinai, N., Pattama, A., Athipanyasilp, A., Patchsung, M., Aphicho, K., Uttamapinant, C., & Horthongkham, N. (2026). CRISPR-Cas13a SHERLOCK assay for rapid and sensitive detection of chikungunya virus. Microbiology Spectrum. https://doi.org/10.1128/spectrum.02298-25
Vancouver
Athipanyasilp N, Saowpak S, Chaimayo C, Angkasekwinai N, Pattama A, Athipanyasilp A, et al. CRISPR-Cas13a SHERLOCK assay for rapid and sensitive detection of chikungunya virus. Microbiology Spectrum. 2026. doi:10.1128/spectrum.02298-25
BibTeX
@article{Athipanyasilp2026,
author = {Athipanyasilp, Niracha and Saowpak, Suwanna and Chaimayo, Chutikarn and Angkasekwinai, Nasikarn and Pattama, Archiraya and Athipanyasilp, Artittaya and Patchsung, Maturada and Aphicho, Kanokpol and Uttamapinant, Chayasith and Horthongkham, Navin},
title = {CRISPR-Cas13a SHERLOCK assay for rapid and sensitive detection of chikungunya virus},
journal = {Microbiology Spectrum},
year = {2026},
doi = {10.1128/spectrum.02298-25}
}
EUVIMED